{"changeSha256":"74eb4d2f7957eefeec1f38c9ec8ca84cbd7fd5ffca8fca14e6fe5e7021c743b4","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Egrifta for HIV-associated abdominal fat","before":"U.S. label record","field":"Status"},{"after":"A growth hormone-releasing factor analogue approved by FDA as Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy.","before":"A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.","before":"The cited DailyMed label identifies Tesamorelin and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9, fda-drugs-bla022505-2010-11-10-9cc235ae6ce0","before":"dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]; U.S. Food and Drug Administration [sources: fda-drugs-bla022505-2010-11-10-9cc235ae6ce0]","before":"U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]","field":"Named organizations"},{"after":"name: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; aliases: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; category: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; status: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9, fda-drugs-bla022505-2010-11-10-9cc235ae6ce0; summary: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9, fda-drugs-bla022505-2010-11-10-9cc235ae6ce0; evidenceNote: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9","before":"name: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; aliases: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; category: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; status: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; summary: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; evidenceNote: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tesamorelin/versions/4/","version":4},"id":"profile:tesamorelin:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Egrifta SV label, and added the Drugs@FDA approval record.","peptideSlugs":["tesamorelin"],"previousChangeEvent":{"path":"/corrections/v1/profiles/tesamorelin/v3.json","sha256":"07a0cff50ac32cbf06f0aa52f638e71ee75c082add6ac4e7e0adc2cea92e625a"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tesamorelin/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=9","verifiedAt":"2026-09-15"},{"id":"fda-drugs-bla022505-2010-11-10-9cc235ae6ce0","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA022505%22&limit=1","verifiedAt":"2026-08-14"}],"subject":{"slug":"tesamorelin","type":"profile"}}
